Study on intervention of warming kidney, promoting blood circulation and detoxification method in prostate cancer

INTERVENTION: HSPC Experimental group:ADT + Shenqi pill;HSPC control group:ADT + Shenqi pill;HSPC Blank group :ADT ;CRPC Experimental group:ADT + Abiraterone + Shenqi pill + Xihuang pill;CRPC control group:ADT + Abiraterone + Shenqi pill + Xihuang pill;CRPC Blank group:ADT + Abiraterone; CONDITION: prostate cancer PRIMARY OUTCOME: Overall survival;progression‐free survival;mismatch repair gene; SECONDARY OUTCOME: Physical condition assessment;appraisal of life quality; Evaluation of TCM symptoms; INCLUSION CRITERIA: According to the "Chinese Society of Clinical Oncology (CSCO) Prostate Cancer Diagnosis and Treatment Guidelines 2020", Fizazi K and other research protocols were formulated. (Organized by the Guidelines Working Committee of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Prostate Cancer 2020. Beijing: People's Health Publishing House 2020, Fizazi K,et al. N Engl J Med, 2019:3 80(13): 1235‐1246. 1. Inclusion criteria for patients in the HSPC experimental group:Metastatic prostate cancer (N1 and M1 stages): differentiate between low tumor burden metastases and high tumor burden metastases; locally advanced prostate cancer cannot be treated with radical prostatectomy or radiotherapy; after radical prostatectomy local recurrence but no further local therapy; distant metastasis after radical prostatectomy; 2. Inclusion criteria for patients in the CRPC experimental group: diagnos